(Q35951855)

11 August 2017

1 reference

title

Cytokines in cancer immunity and immunotherapy (English)

1 reference

11 August 2017

1 reference

Michael H Kershaw

3

0 references

Mark J. Smyth

object named as

Mark J Smyth

series ordinal

1

0 references

Yoshihiro Hayakawa

series ordinal

4

object named as

Yoshihiro Hayakawa

1 reference

11 August 2017

2

Erika Cretney

1 reference

11 August 2017

1 December 2004

1 reference

11 August 2017

Immunological Reviews

1 reference

11 August 2017

202

1 reference

11 August 2017

275-293

1 reference

Cancer immunoediting: from immunosurveillance to tumor escape

11 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Interleukin-12 in anti-tumor immunity and immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The type I interferon receptor: structure, function, and evolution of a family business.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Deficiencies of GM-CSF and Interferon γ Link Inflammation and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Cytokines, tumour-cell death and immunogenicity: a question of choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Differential tumor surveillance by natural killer (NK) and NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Alpha-galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

IL-12 treatment of endogenously arising murine brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Antitumor and antimetastatic activity of IL-23

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Dendritic cells in models of tumor immunity. Role of Flt3 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The central role of CD4(+) T cells in the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Progress in human tumour immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

IL-21 induces the functional maturation of murine NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Inflammatory cells and cancer: think different!

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The intriguing role of polymorphonuclear neutrophils in antitumor reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Infections as a major preventable cause of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

A proinflammatory cytokine inhibits p53 tumor suppressor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The TNF and TNF receptor superfamilies: integrating mammalian biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Tumor necrosis factor or tumor promoting factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Cytokines in non-genotoxic hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The Fas counterattack: cancer as a site of immune privilege

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Countering the 'counterattack' hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Clinical significance of the determination of angiogenic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Vaccination against tumor neovascularization: Promise and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Role of transforming growth factor beta in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Chronic myelogenous leukemia: biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Interleukin-2 and interleukin-15: immunotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Coupling and uncoupling of tumor immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

The nature of the principal type 1 interferon-producing cells in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

Correction: The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0105-2896.2004.00199.X

10.1111/J.0105-2896.2004.00199.X

21 January 2018

Identifiers

DOI

1 reference

11 August 2017

1 reference

PubMed ID

15546400